/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company focused on developing innovative treatments for serious diseases, including cancer, cardiovascular conditions, and immunologic disorders. With a robust portfolio of drugs like Opdivo, Eliquis, and Yervoy, it continues to advance cutting-edge therapies across core therapeutic areas. BMY is set to unveil its fiscal Q4 earnings results before the market opens on Thursday, Feb. 6.
Ahead of this event, analysts expect the Princeton, New Jersey-based company to report a profit of $1.46 per share, down 14.1% from $1.70 per share in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the past four quarters. In the most recent quarter, BMY exceeded the consensus EPS estimate by a margin of 20.8%.